Genetic Testing: Challenges and changes in testing for hereditary cancer syndromes

@article{King2017GeneticTC,
  title={Genetic Testing: Challenges and changes in testing for hereditary cancer syndromes},
  author={Elisabeth King and Suzanne M Mahon},
  journal={Clinical Journal of Oncology Nursing},
  year={2017},
  volume={21},
  pages={589–598}
}
BACKGROUND: The practice of genetic testing for hereditary cancer syndromes has changed dramatically in recent years, and patients often approach oncology nurses requesting information about genetic testing. OBJECTIVES: This article aims to explore changes in cancer genetics, the role of genetics professionals in providing comprehensive genetic care, and the implications of these new developments in genetics for oncology nurses. METHODS: A literature review was conducted and focused on articles… 

Figures from this paper

Genetic Testing: Do Cancer Care Nurses Have a Role?
  • V. Lopez
  • Medicine
    Asia-Pacific journal of oncology nursing
  • 2018
TLDR
Health care professional are faced with many challenges to meet clients’ understanding, expectations, and facilitating their decisions about future management plans as genetic testing is now an integral part of cancer prevention, early detection services, and treatment.
Genetic Service Delivery Models
TLDR
Alternative service delivery models can increase the accessibility of genetic counseling services to at‐risk populations and how oncology nurses can play a supportive role in facilitating the genetic counseling process is discussed.
Test Ordering Practices in Cancer Genetic Counseling
​The widespread use of Next Generation Sequencing (NGS) has allowed multi-gene panel testing to become common practice in clinical cancer genetic testing over the past six years. Over this time,
Coordination of Genetic Care: More Important and Complicated Than it Seems.
  • S. Mahon
  • Medicine
    Journal of the National Comprehensive Cancer Network : JNCCN
  • 2019
TLDR
A case is presented illustrating the potential errors that can occur when genetic care is fragmented and not coordinated, including ordering too much or not enough genetic testing, failing to communicate with the family who is at potential genetic risk, and refusing to communicate what the results of testing mean.

References

SHOWING 1-10 OF 67 REFERENCES
Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing
TLDR
The introduction of next-generation sequencing (NGS) technology in testing for hereditary cancer susceptibility allows testing of multiple cancer susceptibility genes simultaneously, but there are also important limitations that must be considered.
The Evolution of Cancer Risk Assessment in the Era of Next Generation Sequencing
Cancer genetics professionals face a new opportunity and challenge in adapting to the availability of cancer genetic testing panels, now available as a result of Next Generation Sequencing (NGS)
Challenges to clinical utilization of hereditary cancer gene panel testing: perspectives from the front lines
TLDR
While a shift from traditional Sanger sequencing to NGS is occurring in molecular genetic testing for disease susceptibility, there are several obstacles that need to be overcome before widespread adoption of this technology can occur.
Genetics, genomics, and cancer risk assessment
TLDR
Given the experiences and lessons learned in the genetics era, the multidisciplinary model of genetic cancer risk assessment and management will serve as a solid foundation to support the integration of personalized genomic information into the practice of cancer medicine.
Adverse Events in Cancer Genetic Testing: The Third Case Series
TLDR
It is concluded that genetic counseling and testing should be offered by certified genetics providers to minimize the risks, maximize the benefits, and utilize health care dollars most efficiently.
Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
TLDR
In a clinically representative cohort, multigene panel testing for HBOC risk assessment yielded findings likely to change clinical management for substantially more patients than does BRCA1/2 testing alone.
Routine use of gene panel testing in hereditary breast cancer should be performed with caution.
Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory
TLDR
This descriptive study is among the first to report on a large clinical series of patients undergoing panel‐based testing for inherited CRC, and the percentage of patients with ‘actionable’ mutations that would clearly alter cancer screening recommendations per national guidelines decreased.
Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care
TLDR
The use of multigene panels for the assessment of cancer risk beyond the classic predisposition syndromes as a new standard of care in cancer genetics is exhorted.
...
...